Tech & Pharma
ZAI Lab has acquired the license for two pre-clinical drugs for chronic respiratory diseases.
PW Medtech expands its capabilities in medical devices with the acquisition of Beijing Tianxinfu Medical Appliance Co.
The partnership between Fosun and Taizhou Muncipal Hospital will add approximately 2,000 new hospital beds to serve the residents of Taizhou.
Celltrion predicts that it is one year away from approval for Remsima®, a biosimilar based on an originator drug from Janssen Biotech.
The National Cheng Kung University and Fujitsu will develop a cloud computing platform for big data analysis in agriculture and genomics research.
China’s Cellular Biomedicine Group acquires Agreen for US$3.38 million in cash in addition to stock units.
3SBio and DiNonA will develop Leukotuximab, an anti JL-1 antibody indicated for the treatment of acute leukemia.
The partnership between Astellas and Cancer Research Technology will begin with the development of drugs for pancreatic cancer targeting autophagy.
Baxter’s biologic facility in Singapore has been approved by the European Medicines Agency to supply products for hemophiliacs.
ZIOPHARM could receive up to US$72.2 million from Solasia for the anti-cancer drug darinaparsin.